

Customer No. 28880

RECEIVED
CENTRAL FAX CENTER

Confirmation No. 3929

OCT 13 2004


PTO/SB/21 (03-03)


Approved for use through 04/30/2003. OMB 0851-0031

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/771,696
	Filing Date	February 4, 2004
	First Named Inventor	Kazunari Nakao, et al.
	Art Unit	1624
	Examiner Name	Laura Stockton
	Attorney Docket Number	PC 9985B
Total Number of Pages in This Submission	29	

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to a Technology Center (TC)
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input checked="" type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Change of Correspondence Address	<input type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Response to Missing Parts/Incomplete Application	Remarks	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	AUTHORIZATION TO CHARGE THE FEE AND ANY ADDITIONAL FEES AS NECESSARY OR CREDIT ANY OVERPAYMENT TO DEPOSIT ACCOUNT 23-0455 IS HEREBY GIVEN.	

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual	David R. Kurlandsky
Signature	
Date	10/13/04

CERTIFICATE OF TRANSMISSION/MAILING	
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date <u>10/13/04</u>	
Typed or printed	Linda A. Zerby
Signature	
Date	10/13/04

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

USPTO Fax No. 703-872-9306

Confirmation No. 3929

RECEIVED
CENTRAL FAX CENTER

PC9985B

OCT 13 2004

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

APPLICANT : Kazunari Nakao, et al.

EXAMINER : Laura Stockton

SERIAL NO. : 10/771,696

ART UNIT : 1624

FILED : February 4, 2004

PAPER NO :

FOR : ARYL OR HETEROARYL FUSED IMIDAZOLE COMPOUNDS AS
ANTI-INFLAMMATORY AND ANALGESIC AGENTS

Response Under 37 C.F.R § 1.111(a)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

This is in response to the Office Action dated September 13, 2004.

Claims as previously presented are reflected in the listing of claims, which begins on page 2 of this paper.

Remarks/Arguments begin on page 26 of this paper.